What risk should justify implantable cardioverter defibrillator therapy?

摘要: Implantable cardioverter defibrillators (ICDs) were developed to prevent sudden cardiac death in patients with ventricular tachycardia (VT) or fibrillation (VF). Their safety and efficacy have been proved multiple retrospective prospective studies. Many of the published trials directed at secondary prevention for who had already a sustained VT. For primary prevention, information available is limited, as only 2 yet published. Ongoing will probably allow us broaden indications prophylactic ICD implantation. Justification risk be evaluated against complexity implant, latter including not cost but quality life morbidity associated an ICD. However, our efforts still improve stratification decrease procedure.